IL132169A0 - Method and composition for modulating amyloidosis - Google Patents
Method and composition for modulating amyloidosisInfo
- Publication number
- IL132169A0 IL132169A0 IL13216998A IL13216998A IL132169A0 IL 132169 A0 IL132169 A0 IL 132169A0 IL 13216998 A IL13216998 A IL 13216998A IL 13216998 A IL13216998 A IL 13216998A IL 132169 A0 IL132169 A0 IL 132169A0
- Authority
- IL
- Israel
- Prior art keywords
- composition
- amyloidosis
- modulating
- modulating amyloidosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84761697A | 1997-04-28 | 1997-04-28 | |
| PCT/US1998/008463 WO1998048784A2 (en) | 1997-04-28 | 1998-04-28 | Method and composition for modulating amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL132169A0 true IL132169A0 (en) | 2001-03-19 |
Family
ID=25301065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13216998A IL132169A0 (en) | 1997-04-28 | 1998-04-28 | Method and composition for modulating amyloidosis |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0979086A2 (de) |
| JP (1) | JP2002504895A (de) |
| AU (1) | AU7260398A (de) |
| CA (1) | CA2285948A1 (de) |
| IL (1) | IL132169A0 (de) |
| WO (1) | WO1998048784A2 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514686B2 (en) | 1997-04-28 | 2003-02-04 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| JP4503180B2 (ja) * | 1998-08-14 | 2010-07-14 | ジーピーアイ ニル ホールディングス インコーポレイテッド | 視覚および記憶障害のための組成物および使用法 |
| JP2000072749A (ja) * | 1998-08-24 | 2000-03-07 | Mitsui Chemicals Inc | キノリン誘導体を用いるアポトーシス誘導剤 |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819382D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| CA2346689A1 (en) | 1998-10-08 | 2000-04-20 | Gregor James Macdonald | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| GB9824207D0 (en) * | 1998-11-04 | 1998-12-30 | Zeneca Ltd | Neurological disorders |
| WO2000055318A2 (en) | 1999-03-15 | 2000-09-21 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| EP1210422A2 (de) * | 1999-08-20 | 2002-06-05 | Active Pass Pharmaceuticals, Inc. | Humaner abc2 transporter und dessen verwendungen |
| AR027878A1 (es) * | 1999-11-05 | 2003-04-16 | Wyeth Corp | Metodos para identificar y utilizar compuestos inhibidores de amiloides |
| WO2001078709A2 (en) * | 2000-04-12 | 2001-10-25 | Minerva Biotechnologies Corporation | Treatment of neurodegenerative disease |
| US20020169137A1 (en) * | 2001-02-09 | 2002-11-14 | Active Pass Pharmaceuticals, Inc. | Regulation of amyloid precursor protein expression by modification of ABC transporter expression or activity |
| AU2002304931A1 (en) * | 2001-06-08 | 2002-12-23 | University Of British Columbia | Methods for treating disorders of the nervous and reproductive systems |
| FR2850022B1 (fr) * | 2003-01-22 | 2006-09-08 | Centre Nat Rech Scient | Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications |
| WO2005105063A1 (en) * | 2004-05-03 | 2005-11-10 | Universita' Degli Studi Di Firenze | Pharmaceutical compositions containing serms for the treatment of alzheimer's disease |
| US20060084672A1 (en) * | 2004-10-20 | 2006-04-20 | The Hospital For Sick Children | Method for modification of y-secretase activity through inhibition of Fkbp13 |
| GB0509317D0 (en) * | 2005-05-06 | 2005-06-15 | Clarke Anthony | Pharmaceutical formulation of apomorphine |
| WO2011017319A1 (en) | 2009-08-03 | 2011-02-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating disorders associated with protein polymerization |
| US9072772B2 (en) | 2009-11-05 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating disorders associated with protein aggregation |
| US8809617B2 (en) | 2009-11-05 | 2014-08-19 | The University of Pittsburgh—Of the Commonwealth System of Higher Education | Automated high-content live animal drug screening using C. elegans |
| WO2011056222A1 (en) * | 2009-11-05 | 2011-05-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating disorders associated with protein aggregation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385915A (en) * | 1990-05-16 | 1995-01-31 | The Rockefeller University | Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation |
| GB9205670D0 (en) * | 1992-03-16 | 1992-04-29 | Indena Spa | New derivatives of physostigmine,their use and pharmaceutical formulations containing them |
| US5466696A (en) * | 1992-09-10 | 1995-11-14 | Warner Lambert Company | Tacrine and cytochrome P450 oxidase inhibitors and methods of use |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
| US6133299A (en) * | 1993-02-25 | 2000-10-17 | Warner-Lambert Company | Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds |
| US5753640A (en) * | 1995-06-07 | 1998-05-19 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| US5635496A (en) * | 1993-03-09 | 1997-06-03 | University Of Utah Research Foundation | Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome |
| WO1996004915A1 (en) * | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
-
1998
- 1998-04-28 EP EP98919923A patent/EP0979086A2/de not_active Withdrawn
- 1998-04-28 JP JP54725498A patent/JP2002504895A/ja active Pending
- 1998-04-28 AU AU72603/98A patent/AU7260398A/en not_active Abandoned
- 1998-04-28 WO PCT/US1998/008463 patent/WO1998048784A2/en not_active Ceased
- 1998-04-28 IL IL13216998A patent/IL132169A0/xx unknown
- 1998-04-28 CA CA002285948A patent/CA2285948A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2285948A1 (en) | 1998-11-05 |
| JP2002504895A (ja) | 2002-02-12 |
| WO1998048784A2 (en) | 1998-11-05 |
| AU7260398A (en) | 1998-11-24 |
| WO1998048784A3 (en) | 1999-08-12 |
| EP0979086A2 (de) | 2000-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL142725A0 (en) | Method and composition for modulating amyloidosis | |
| AU7260398A (en) | Method and composition for modulating amyloidosis | |
| HUP9904009A3 (en) | Method and novel compounds for use therein | |
| ZA989400B (en) | Method and composition | |
| ZA972187B (en) | Method and composition for skin lightening | |
| GB9609379D0 (en) | Mechanism and method | |
| CY2506B1 (en) | Composition | |
| SG71810A1 (en) | Coating method and coating composition used therein | |
| GB2298713B (en) | Method and composition | |
| ZA989398B (en) | Method and composition (l) | |
| EP0884044A4 (de) | Haarbehandlungsmittel | |
| GB9624501D0 (en) | Insecticial compositions and method | |
| GB9803506D0 (en) | Composition and method | |
| GB2329584B (en) | Cosmetic composition and its producing method | |
| GB2318356B (en) | Composition and method | |
| GB9408342D0 (en) | Method and composition | |
| GB9707251D0 (en) | Novel method and compounds | |
| GB9414888D0 (en) | Method and composition | |
| GB9419087D0 (en) | Method and composition | |
| GB9717972D0 (en) | Labelling composition and method | |
| GB9619261D0 (en) | Pesticidal composition and method | |
| GB9721425D0 (en) | Composition and method | |
| GB9720422D0 (en) | Composition and method | |
| GB9720017D0 (en) | Composition and method | |
| ZA989401B (en) | Method and composition |